3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Bevacizumab
30
pembrolizumab
29
Oxaliplatin
28
Leucovorin
25
Fluorouracil
24
Irinotecan
22
Cetuximab
22
Capecitabine
19
Nivolumab
15
Specimen Handling
12
atezolizumab
11
Panitumumab
11
Colonoscopy
9
Carboplatin
9
regorafenib
8
Biopsy
8
trifluridine tipiracil drug combination
7
Trifluridine
7
Paclitaxel
7
Aspirin
7
balstilimab
6
Standard of Care
6
Cisplatin
6
tislelizumab
5
encorafenib
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Immunoglobulin G
5
Folfox protocol
5
Disulfides
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Colorectal Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled